Company Comparison
Editas Medicine vs 23andMe
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | Editas Medicine | 23andMe |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | located in Cambridge, Massachusetts | South San Francisco, California |
| Founded | — | 2006 |
| Status | Active | Active |
| Last Funding Stage | — | — |
| Total Funding | — | — |
| Valuation | — | — |
What They Build
Editas Medicine
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology.
23andMe
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.
Key Investors
Sector Overlap
Both Editas Medicine and 23andMe operate in Biotech.
Browse all Biotech companies →Websites
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Now in alpha with select funds. 14-day trial available.